PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Saladax Biomedical, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Saladax Biomedical, Inc. Announces Presentation of CEPAC - TDM Study of Paclitaxel in Non-Small Cell Lung Cancer At 2015 ASCO Meeting - Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Chemotherapy - Saladax.com
Saladax Biomedical, Inc. Announces Presentation of CEPAC - TDM Study of Paclitaxel in Non-Small Cell Lung Cancer At 2015 ASCO Meeting

 

NewswireToday - /newswire/ - Bethlehem, PA, United States, 2015/06/05 - Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Chemotherapy - Saladax.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Saladax Biomedical, Inc. presented results today from the largest, randomized, prospective dose adjustment-therapeutic drug monitoring (TDM) trial ever conducted in oncology: evaluating 304 patients over six years (abstract # 8051). The CEPAC-TDM phase III study in advanced Non-Small Cell Lung Cancer (NSCLC) patients (ClinicalTrials.gov Identifier NCT01326767) compared two arms one with dose optimization [pharmacokinetically (PK)-guided] to one with standard dosing. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015 taking place in Chicago, Illinois. The presentation is available on the Saladax website.

CEPAC-TDM was a study of paclitaxel (PTX) dosing in NSCLC patients receiving PTX in combination with carboplatin on a 3-weekly schedule. Standard dosing of chemotherapy does not account for the many differences between patients which make drug exposure highly variable, and variability of exposure can lead to severe toxicity and/or shorter survival.

Patients with advanced NSCLC receiving PTX/carboplatin chemotherapy were enrolled at nine German and one Swiss institution. In the PK-Guided Arm the majority of patients saw a significant eduction in the dose with fewer toxic side effects and the same survival as the Standard Arm. This well controlled, randomized study showed that using PK-Guided dosing with 3-weekly PTX in NSCLC patients results in a clinically significant reduction of both neutropenia and neuropathy compared to Standard dosing. The reduction in neuropathy is particularly important because it is impossible to treat or prevent this often debilitating side effect. The lower average PTX doses only reduced toxicity and did not reduce efficacy, confirming the value of PK-guided dosing with chemotherapy patients.

At the same conference, interim study results from a similar randomized study in NSCLC (ClinicalTrials.gov Identifier NCT02058433) reported from Shanghai Pulmonary Hospital in China presented very consistent trends further demonstrating the value of PK-Guided dosing (abstract # 8052).

About Saladax Biomedical, Inc.

Saladax Biomedical (saladax.com) is a leader in the development high-value diagnostic services and products. Products that deliver actionable data to help physicians select and optimize the use of current and new pharmaceutical products to improve health and positively impact the economics of care: diagnostics that make a difference. Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Saladax Biomedical, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Saladax Biomedical, Inc. Announces Presentation of CEPAC - TDM Study of Paclitaxel in Non-Small Cell Lung Cancer At 2015 ASCO Meeting

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Salvatore Salamone - Saladax.com 
610-419-6731 ssalamone[.]saladax.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Saladax Biomedical, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Saladax Biomedical, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  S&A Capital Partner Ltd

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)